Ralliant (NYSE:RAL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Ralliant (NYSE:RAL) from a hold rating to a buy rating in a report issued on Saturday.

RAL has been the topic of a number of other reports. Barclays boosted their price target on shares of Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Evercore assumed coverage on shares of Ralliant in a research note on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price objective on the stock. TD Cowen boosted their target price on Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 20th. Finally, Morgan Stanley upped their target price on Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Ralliant presently has an average rating of “Moderate Buy” and a consensus price target of $71.45.

Ralliant Trading Down 0.6%

NYSE:RAL opened at $69.78 on Friday. The stock has a market cap of $7.81 billion and a price-to-earnings ratio of -6.38. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. Ralliant has a 1 year low of $37.27 and a 1 year high of $75.41. The business has a fifty day moving average of $65.62 and a 200-day moving average of $53.28.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The business had revenue of $534.60 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The business’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities analysts predict that Ralliant will post 2.64 earnings per share for the current year.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is presently -1.83%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Danske Bank A S bought a new stake in shares of Ralliant during the 4th quarter worth $25,000. V Square Quantitative Management LLC acquired a new stake in shares of Ralliant during the fourth quarter worth $26,000. Allworth Financial LP raised its position in shares of Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares during the period. Palisade Asset Management LLC purchased a new stake in shares of Ralliant during the third quarter valued at $26,000. Finally, BOKF NA purchased a new stake in shares of Ralliant during the third quarter valued at $29,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.